Annexon, Inc. Common Stock
ANNXAnnexon, Inc. is a biotechnology company focused on developing therapies for neurodegenerative and autoimmune diseases. It specializes in targeting the complement system to address conditions such as Alzheimer’s disease, multiple sclerosis, and other immune-related disorders. The company's approach involves creating monoclonal antibodies that modulate the immune response to prevent cellular damage.
Company News
Annexon, a biopharmaceutical company, announced a public offering of 25,096,153 shares of common stock and pre-funded warrants, expecting to raise $75 million to support its neuroinflammation research platform.
Here is how Annexon, Inc. (ANNX) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. Shares of Cintas Corporation (NASDAQ: CTAS) rose sharply during Wednesday’s session after the company reported better-than-expected third-quarter financial results and raised FY24 guidance. Cintas posted GAAP earnings of $3.84 per share, beating market est...
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.
